In particular, CTLA4-Ig treatment significantly represses all subtypes of peripheral blood-derived Tregs in early RA patients differently from IL-6R and TNF-β inhibitors whose effect was limited to CTLA4pos cells, which represent activated Tregs directly related to the disease burden [32]. The gene discussed is IL6R; the disease is rheumatoid arthritis.